What is Zacks Research's Estimate for Qiagen Q1 Earnings?

Qiagen (NYSE:QGEN - Free Report) - Research analysts at Zacks Research decreased their Q1 2025 earnings estimates for shares of Qiagen in a research note issued on Wednesday, February 26th. Zacks Research analyst R. Department now forecasts that the company will post earnings per share of $0.48 for the quarter, down from their prior forecast of $0.50. The consensus estimate for Qiagen's current full-year earnings is $2.26 per share. Zacks Research also issued estimates for Qiagen's Q2 2025 earnings at $0.56 EPS, Q3 2025 earnings at $0.58 EPS, FY2025 earnings at $2.25 EPS, Q2 2026 earnings at $0.60 EPS, Q3 2026 earnings at $0.61 EPS, Q4 2026 earnings at $0.67 EPS and FY2026 earnings at $2.40 EPS.

Qiagen (NYSE:QGEN - Get Free Report) last announced its quarterly earnings results on Wednesday, February 5th. The company reported $0.61 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.60 by $0.01. Qiagen had a net margin of 4.23% and a return on equity of 13.92%.

A number of other brokerages have also issued reports on QGEN. Robert W. Baird lowered shares of Qiagen from an "outperform" rating to a "neutral" rating and cut their price target for the stock from $52.00 to $42.00 in a report on Wednesday, February 19th. Baird R W lowered shares of Qiagen from a "strong-buy" rating to a "hold" rating in a report on Wednesday, February 19th. Jefferies Financial Group reissued a "buy" rating and issued a $52.50 price target (up previously from $40.83) on shares of Qiagen in a report on Tuesday, December 10th. Morgan Stanley reaffirmed an "equal weight" rating and set a $46.67 target price (down previously from $48.61) on shares of Qiagen in a research note on Monday, January 6th. Finally, UBS Group cut their target price on shares of Qiagen from $50.00 to $48.00 and set a "neutral" rating on the stock in a research note on Friday, February 7th. Seven analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $47.71.

Remove Ads

Qiagen Trading Up 3.5 %

Qiagen stock traded up $1.35 during trading hours on Monday, reaching $39.90. The stock had a trading volume of 2,082,614 shares, compared to its average volume of 1,254,064. The stock has a market cap of $8.85 billion, a PE ratio of 111.11, a PEG ratio of 2.39 and a beta of 0.44. Qiagen has a 52 week low of $37.63 and a 52 week high of $49.30. The company has a debt-to-equity ratio of 0.38, a current ratio of 3.61 and a quick ratio of 3.09. The company has a fifty day simple moving average of $42.28 and a 200-day simple moving average of $42.72.

Institutional Investors Weigh In On Qiagen

Hedge funds have recently bought and sold shares of the business. Brown Brothers Harriman & Co. bought a new stake in Qiagen during the fourth quarter worth about $37,000. Geneos Wealth Management Inc. boosted its stake in Qiagen by 41.5% during the fourth quarter. Geneos Wealth Management Inc. now owns 856 shares of the company's stock worth $38,000 after acquiring an additional 251 shares in the last quarter. EverSource Wealth Advisors LLC boosted its stake in Qiagen by 152.5% during the fourth quarter. EverSource Wealth Advisors LLC now owns 871 shares of the company's stock worth $39,000 after acquiring an additional 526 shares in the last quarter. Wilmington Savings Fund Society FSB bought a new stake in Qiagen during the third quarter worth about $53,000. Finally, Smartleaf Asset Management LLC boosted its stake in Qiagen by 148.0% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,399 shares of the company's stock worth $63,000 after acquiring an additional 835 shares in the last quarter. Institutional investors own 70.00% of the company's stock.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.